Stage I Grade 3 Follicular Lymphoma Completed Phase 2 Trials for Deferasirox (DB01609)

IndicationStatusPhase
DBCOND0029477 (Stage I Grade 3 Follicular Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01273766Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesSupportive Care